Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DermaVir, a novel HIV immunisation technology.

Franco Lori1, Jeffrey Trocio, Nyasha Bakare

  • 1Research Institute for Genetic and Human Therapy, 2233 Wisconsin Ave. Suite 503, Washington, DC 20007, USA. rightpv@tin.it

Vaccine
|March 10, 2005
PubMed
Summary

DermaVir, a topical immunisation targeting Langerhans cells, shows promise in HIV treatment. It suppressed viral load rebound in macaques when combined with antiretroviral drugs, improving survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring Hydroxytyrosol as a Promising Virucidal Agent: In Silico and In Vitro Insights into Enveloped Viruses.

Current issues in molecular biology·2026
Same author

Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: a randomized trial.

Infection·2026
Same author

Bedaquiline Monotherapy for Multibacillary Leprosy.

The New England journal of medicine·2024
Same author

Correction: Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients.

PloS one·2024
Same author

Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of Aggressive Cancers.

Current medicinal chemistry·2024
Same author

A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.

Trials·2024

Area of Science:

  • Immunology
  • Virology
  • Dermatology

Background:

  • Langerhans cells (LC) are key immune cells in the skin, crucial for processing antigens.
  • Effective HIV treatment requires novel approaches targeting viral reservoirs and immune responses.

Purpose of the Study:

  • To evaluate DermaVir, a topical immunisation targeting LC, as a novel HIV treatment strategy.
  • To assess DermaVir's ability to induce T cell-mediated immunity and suppress viral load.

Main Methods:

  • DermaVir delivers HIV DNA to LC, stimulating immune responses.
  • Studies involved chronically infected macaques treated with DermaVir and antiretroviral drugs.

Main Results:

  • DermaVir induced T cell-mediated immune responses with broad specificity.

Related Experiment Videos

  • In macaques, DermaVir suppressed viral load rebound after treatment interruption.
  • Combination therapy improved survival rates in treated macaques.

    • Conclusions:

    • DermaVir represents a promising topical immunisation for HIV treatment.
    • Its unique mechanism of action supports combination therapy with existing antiretroviral drugs.